Last checked at 
ZURICH, April 20 (Reuters) - A German scientist studying
rare blood clots linked to AstraZeneca's COVID-19
vaccine said on Tuesday that Johnson & Johnson had
agreed to collaborate with him on research into similar events
associated with its own COVID-19 shot.
"We agreed today with the company that we will work
together," Andreas Greinacher, a scientist at Greifswald
University, said during a press conference where he outlined his
work seeking to explain the causes of the very rare clots that
developed in people given AstraZeneca's shot.
Greinacher's comments came as J&J said it stood ready to
restart its COVID-19 vaccine in Europe, where the region's
medical regulator on Tuesday said the benefits of the shot
outweigh the risk of very rare, potentially lethal blood clots.
(Reporting by John Miller)
